



WAY-262611

Cat. No.:	OB0225WX-1716
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and HPLC.
Size:	5 mg; 10 mg; 25 mg; 50 mg; 100 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	WAY262611 is a Wnt/β-catenin agonist that functions as a Dkk1 inhibitor, yielding an EC50 of 0.63 μM in TCF-luciferase reporter assays.
Synonym	1123231-07-1; (1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine; [1-(4-naphthalen-2-yl)pyrimidin-2-yl]piperidin-4-yl)methanamine; {1-[4-(naphthalen-2-yl)pyrimidin-2-yl]piperidin-4-yl}methanamine; WAY262611 2HCl; DKK1 inhibitor; WAY262611; ({1-[4-(2-naphthyl)pyrimidin-2-yl]piperidin-4-yl}methyl)amine; [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine
CAS No.	1123231-07-1
Compound CID	25199517
Formula	C ₂₀ H ₂₂ N ₄
Formula Weight	318.42

Specification

Targets&IC50	β-catenin (TCF-Luciferase assay): 0.63 μM
Relative Density	1.169 g/cm ³
IUPAC Name	[1-(4-Naphthalen-2-yl)pyrimidin-2-yl]piperidin-4-yl)methanamine
InChI	InChI=1S/C20H22N4/c21-14-15-8-11-24(12-9-15)20-22-10-7-19(23-20)18-6-5-16-3-1-2-4-17(16)13-18/h1-7,10,13,15H,8-9,11-12,14,21H2
InChI Key	QHLITPHIARVDJI-UHFFFAOYSA-N
SMILES string	C1CN(CCC1CN)C2=NC=CC(=N2)C3=CC4=CC=CC=C4C=C3



Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	WAY-262611 is employed in musculoskeletal research as a small molecule Dkk1 inhibitor to study the potentiation of Wnt signaling and its effects on bone density and mineralisation.

Library Information

Target	Wnt/ β -Catenin
Receptor	β -Catenin
Pathways	Stem cells; Cytoskeletal signaling
Plate Number	AOCL-22
Plate Location	h11
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	42 mg/mL; 131.90 mM